Response to systemic chemotherapy is heavily dependent upon the intrinsic tumour properties, with the most favourable pathological complete response (pCR) rates in cancers overexpressing human epidermal growth factor receptor-2 (HER2), or of the triple negative molecular phenotype [4,5]. This evidence concerns the gene ERBB2 and cancer.